Shots:
- Alvotech & Dr. Reddy’s have signed a license & supply agreement to commercialize AVT03 under which Alvotech will handle the development & manufacturing activities. Dr. Reddy will get regulatory & commercial rights exclusively in US and semi-exclusively in the EU & UK
- Alvotech will receive an upfront, regulatory & commercial milestones as well as sales-based payments
- Additionally, in Jan 2024, the company reported top-line data of a PK study assessing safety, PK & tolerability of AVT03 vs Prolia in healthy adults. A confirmatory efficacy & safety study in patients & a PK study of AVT03 vs Xgeva in healthy adults are ongoing
Ref: Alvotech | Image: Alvotech & Dr. Reddy| Press Release
Related News:- Sandoz Reports EC’s Approval of Wyost and Jubbonti (Biosimilars, Xgeva and Prolia)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
